Gavel with drugs According to the suit, those manufacturers have aggressively increased their prices for Insulin far beyond the prices they would have charged if there were no kickback scheme. (Photo: Shutterstock)

A group of drug manufacturers and pharmacy benefit managers are accused in a class action suit of artificially inflating prices for analog insulin.

The suit claims drug manufacturers Eli Lilly and Co., Novo Nordisk and Sanofi Aventis U.S. maintain or increase their sales by paying bribes and kickbacks to pharmacy benefit managers CVS, Express Scripts, Medco Health Solutions, United Health and OptumRX in the form of rebates, fees, discounts or other payments or financial incentives in exchange for inclusion or favorable placement of the manufacturers’ respective Insulin products on the defendant’s formularies.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

 

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.